CURB 906
Alternative Names: CUBT-906; CURB-906Latest Information Update: 06 Oct 2022
At a glance
- Originator Connectyx Technologies
- Developer Curative Biotechnology
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 06 Oct 2022 Curative Biotechnology plans for phase I/II IND submission for the treatment of Glioblastoma in the US, by 2024 (Curative Biotechnology pipeline, October 2022)
- 24 Aug 2021 Preclinical trials in Glioblastoma (In children) in USA (Parenteral) (Curative Biotechnology pipeline, August 2021).
- 29 Apr 2021 Connectyx Technologies is now called Curative Biotechnology